Over recent decades biotechnology has made significant advances owing to the emergence of powerful biochemical and biophysical instrumentation. The development of such technologies has enabled high-throughput assessment of compounds, the implementation of recombinant DNA technology, and large-scale manufacture of monoclonal antibodies. Such innovations have ultimately resulted in the current experienced biopharmaceutical stronghold in the therapeutic market. Yet aggregate prediction and profiling remains a challenge in the formulation of biopharmaceuticals due to artifacts associated with each analytical method. We review some emerging trends and novel technologies that offer a promising potential for accurately predicting and profiling protein aggregation at various stages of biopharmaceutical product design. © 2013 Elsevier Ltd.
CITATION STYLE
Hamrang, Z., Rattray, N. J. W., & Pluen, A. (2013, August). Proteins behaving badly: Emerging technologies in profiling biopharmaceutical aggregation. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2013.05.004
Mendeley helps you to discover research relevant for your work.